{"id":179056,"date":"2020-01-12T13:39:41","date_gmt":"2020-01-12T13:39:41","guid":{"rendered":"https:\/\/bm.dev.synology.me\/?p=179056"},"modified":"2020-01-12T13:39:41","modified_gmt":"2020-01-12T13:39:41","slug":"unul-dintre-cele-mai-mari-grupuri-farmaceutice-din-lume-administrateaza-in-mod-aleatoriu-un-medicament-in-valoare-de-doua-milioane-de-dolari-starnind-critici-cu-privire-la-problemele-etice-pe-care-le","status":"publish","type":"post","link":"https:\/\/bm.dev.synology.me\/?p=179056","title":{"rendered":"Unul dintre cele mai mari grupuri farmaceutice din lume administrateaz\u0103 \u00een mod aleatoriu un medicament \u00een valoare de dou\u0103 milioane de dolari, st\u00e2rnind critici cu privire la problemele etice pe care le ridic\u0103 o astfel de decizie"},"content":{"rendered":"<p>\nGrupul farmaceutic Novartis a lansat un program de tip loterie prin care ofer\u0103 \u00een mod gratuit doze produse prin intermediul terapiei genetice, st\u00e2rnind critici din partea grupurilor de pacien\u0163i, ace\u015ftia fiind de p\u0103rere c\u0103 modul de distribuire al unui remediu dedicat trat\u0103rii bebelu\u015filor este total inadecvat, potrivit Wall Street Journal.<\/p>\n<p>\nZolgensma, un medicament administrat intravenos o singur\u0103 dat\u0103, vizeaz\u0103 bolile mortale ale c\u0103ror victime nu \u00ee\u015fi pot controla mu\u015fchii \u015fi se vinde \u00een prezent doar \u00een Statele Unite. Av\u00e2nd un pre\u0163 de 2,1 milioane de dolari, este cel mai scump medicament din lume.<\/p>\n<p>\nProgramul global de administrare a medicamentului ia \u00een calcul un num\u0103r limitat de oameni ce sufer\u0103 de atrofie muscular\u0103 spinal\u0103 (AMS), pacien\u0163ii afl\u00e2ndu-se \u00een afara Statelor Unite. \u00cens\u0103 mai multe grupuri de pacien\u0163i au criticat mi\u015fcarea, subliniind problemele etice cu care se confrunt\u0103 produc\u0103torii de medicamente \u00een ceea ce prive\u015fte alegerea beneficiarilor.<\/p>\n<p>\nCompaniilor le este permis s\u0103 ofere gratis medicamente neaprobate \u0163\u0103rilor dispuse s\u0103 intre \u00een programe dedicate tratamentelor de tip experimental, programe ce sunt valabile doar pentru pacien\u0163ii \u00een st\u0103ri extrem de grave.<\/p>\n<p>\nAbordarea pe care grupul farmaceutic o lanseaz\u0103 vine \u00een urma cererilor tot mai mari ale medicamentului \u00een \u0163\u0103ri unde Zolgensma nu a fost \u00eenc\u0103 aprobat. \u00cen mod normal, produc\u0103torii se confrunt\u0103 cu un num\u0103r moderat de cereri de medicamente, num\u0103rul \u0163in\u00e2nd cont at\u00e2t de beneficii, c\u00e2t \u015fi de pericole.<\/p>\n<p>\nPrin intermediul programului, doctorii pot trimite cereri de tratare, pacien\u0163ii eligibili intr\u00e2nd \u00eentr-un proces de extragere la fiecare dou\u0103 s\u0103pt\u0103m\u00e2ni. AveXis, unitatea din cadrul Novartis care produce medicamentul, poate distribui circa 100 de doze gratuite pe an. Doar \u00een Europa, aproximativ 1.600 de copii sufer\u0103 de tipul 1 de AMS, cea mai sever\u0103 form\u0103 pe care o poate lua atrofia.<\/p>\n<p>\n&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Grupul farmaceutic Novartis a lansat un program de tip loterie prin care ofer\u0103 \u00een mod gratuit doze produse prin intermediul terapiei genetice, st\u00e2rnind critici din partea grupurilor de pacien\u0163i, ace\u015ftia fiind de p\u0103rere c\u0103 modul de distribuire al unui remediu dedicat trat\u0103rii bebelu\u015filor este total inadecvat, potrivit Wall Street Journal. Zolgensma, un medicament administrat intravenos [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[510],"tags":[246,7688,9108,323,484],"class_list":["post-179056","post","type-post","status-publish","format-standard","hentry","category-actualitate","tag-crestere","tag-critici","tag-decizie","tag-medicamente","tag-probleme"],"_links":{"self":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/179056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=179056"}],"version-history":[{"count":0,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/179056\/revisions"}],"wp:attachment":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=179056"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=179056"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=179056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}